https://www.zacks.com/stock/news/2254098/abbvie-abbv-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2254098
Apr 11, 2024 - The latest trading day saw AbbVie (ABBV) settling at $167.52, representing a -0.89% change from its previous close.
zc:1915502141459700071
0
https://www.zacks.com/stock/news/2253493/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2253493
Apr 10, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
zc:-3544081025948954067
0
https://www.zacks.com/stock/news/2253351/syros-syrs-up-on-fda-fast-track-tag-for-tamibarotene-in-aml?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253351
Apr 10, 2024 - The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
zc:-981502385335474950
0
https://www.zacks.com/commentary/2252707/top-stock-reports-for-abbvie-salesforce-general-electric?cid=CS-ZC-FT-research_daily-2252707
Apr 09, 2024 - Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Salesforce, Inc. (CRM) and General Electric Company (GE).
zc:2624957013781475806
0
https://www.zacks.com/stock/news/2251543/aldeyra-aldx-stock-rallies-43-in-one-week-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2251543
Apr 06, 2024 - Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
zc:-6587684223321157219
0
https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvo-s-new-m-as-fda-nod-to-jnj-mrk-pah-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2247400
Mar 28, 2024 - While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
zc:-4251459591006756089
0
https://www.zacks.com/stock/news/2245659/abbvie-abbv-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2245659
Mar 25, 2024 - AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.
zc:4117404813198848647
0
https://www.zacks.com/stock/news/2245594/why-abbvie-abbv-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2245594
Mar 25, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
zc:246553978233480683
0
https://www.zacks.com/commentary/2242883/top-analyst-reports-for-mastercard-abbvie-salesforce?cid=CS-ZC-FT-research_daily-2242883
Mar 19, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AbbVie Inc. (ABBV) and Salesforce, Inc. (CRM).
zc:9168976599187792448
0
https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001
Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
0
fool:-6439001316408559179
0